US20020107292A1 - Primary composition comprising a lipophilic bioactive compound - Google Patents

Primary composition comprising a lipophilic bioactive compound Download PDF

Info

Publication number
US20020107292A1
US20020107292A1 US10/057,660 US5766002A US2002107292A1 US 20020107292 A1 US20020107292 A1 US 20020107292A1 US 5766002 A US5766002 A US 5766002A US 2002107292 A1 US2002107292 A1 US 2002107292A1
Authority
US
United States
Prior art keywords
composition according
bioactive compound
lipophilic bioactive
primary composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/057,660
Other languages
English (en)
Inventor
Karlheinz Bortlik
Francoise Saucy
Eliane Duruz
Myriam Richelle
Pierre Lambelet
Markus Baur
Andrea Pfeifer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAUR, MARKUS, PFEIFER, ANDREA M. A., BORTLIK, KARLHEINZ, DURUZ, ELAINE, LAMBELET, PIERRE, RICHELLE, MYRIAM, SAUCY, FRANCOISE
Publication of US20020107292A1 publication Critical patent/US20020107292A1/en
Priority to US11/004,409 priority Critical patent/US20050106219A1/en
Priority to US11/553,847 priority patent/US7588781B2/en
Priority to US12/353,730 priority patent/US8455004B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
    • A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
    • A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/986—Milk; Derivatives thereof, e.g. butter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a primary composition comprising a lipophilic bioactive compound and to an oral composition comprising the primary composition and its process of preparation.
  • compositions available on the market that include a lipophilic bioactive compound, namely lycopene, are already known.
  • Lycopene is a natural product which is known to have multiple roles, in particular that of an antioxidant. Lycopene is present in various natural products, in particular tomatoes, melons, guavas and grapefruit.
  • the composition generally available on the market which comprises lycopene is an oleoresin. The problem with this oleoresin is that it has been found that the lycopene present therein is insufficiently bioavailable.
  • European patent 278 284 relates to a pulverulent composition comprising a synthetic carotenoid.
  • the problem with this composition is that it cannot be used in the food field and, moreover, it is envisaged for a coloring purpose.
  • a primary composition that includes at least one lipophilic bioactive compound and a whey protein in an amount effective to increase the bioavailability of the lipophilic bioactive compound.
  • the lipophilic bioactive compound is advantageously obtained, extracted, enriched or purified from a plant, microorganism, yeast or product of animal origin.
  • the preferred form of the primary composition is as an additive in a foodstuff for oral administration, such as in a food supplement, in a cosmetic preparation or in a pharmaceutical preparation.
  • the invention also relates to methods of forming the primary composition, the food supplement, cosmetic preparation or pharmaceutical preparation containing the same, and to a method for protecting skin tissue against ageing by administering to a subject in need of such protection one of the primary, oral, or cosmetic compositions disclosed herein.
  • the process for the preparation of a primary composition comprises associating the whey protein with the lipophilic bioactive compound under conditions sufficient to form the composition a mixture.
  • the composition may be formed by dissolving the whey protein in water to form a first solution, dissolving the lipophilic bioactive compound in a solvent to form a second solution, combining the two solutions, and evaporating the solvent to form the composition as a dispersion.
  • the composition may be formed by mixing the lipophilic bioactive compound with a solvent to form a first mixture, mixing the first mixture with the whey protein in the form of a powder to form a second mixture and evaporating the solvent from the second mixture to produce the composition as a dry powder.
  • the present invention relates to a primary composition comprising a lipophilic bioactive compound and a whey protein.
  • bioactive compound is understood to mean a compound having a beneficial effect on the human or animal metabolism.
  • the present invention now makes available to the consumer an improved composition obtained from natural products. As will be explained further below, protection and enhancement of the lipophilic bioactive compound is also targeted according to the invention.
  • the lipophilic bioactive compound is obtained, extracted, enriched or purified starting from a plant, microorganism, yeast or product of animal origin.
  • the term “obtained” is understood to mean that the bioactive product is directly available commercially.
  • the term “extracted” is understood to mean that the bioactive principle has been extracted.
  • the term “enriched” is understood to mean that the non-bioactive compounds have been separated as much as possible.
  • the term “purified” is understood to mean that only the bioactive compound is recovered.
  • the plant is chosen from the group consisting of tomatoes (i.e., whole tomato, tomato extract, tomato flesh, tomato puree, tomato skin, with or without the seeds), soya, green tea, green coffee beans, spices such as ginger or others, grapes, cocoa and cereals.
  • the microorganism can be any type of bacterium which produces a lipophilic bioactive compound.
  • a probiotic microorganism in particular a lactic acid bacterium, can be envisaged as microorganism.
  • the yeast can be any yeast which produces a lipophilic bioactive compound, for example a Saccharomyces.
  • the product of animal origin is chosen from the group consisting of a liver extract and a milk fraction.
  • milk fraction is understood to mean any part of the milk.
  • the lipophilic bioactive compound is chosen from the group consisting of carotenoids, polyphenols, lipophilic vitamins, flavonoids, isoflavones, curcuminoids, ceramides, proanthocyanidins, terpenoids, sterols, phytosterols, sterol esters, tocotrienols, squalene and retinoids, alone or as a mixture.
  • Carotenoids are present in particular in tomatoes, carrots, yellow peaches, apricots and oranges.
  • Lycopene is a carotenoid which is particularly favored in the present composition.
  • Polyphenols are present in particular in green tea, coffee, cocoa or red wine.
  • Lipophilic vitamins are present in particular in numerous vegetables. Flavonoids and isoflavones are present in particular in soya, tea, onions or wine. Curcuminoids are present in particular in ginger. Ceramides are glycolipids present in particular in yeast derivatives and derivatives of animal origin. Proanthocyanidins are flavonoids present in particular in grapes. Terpenoids are present in spices. Sterols, phytosterols and sterols esters are present in particular in vegetable oils, seeds, nuts and vegetables. Tocotrienols are present in particular in rice bran, barley, wheat, palm oil, rye and oats. Squalene is present in particular in fish liver, olive oil, wheat germ oil or rice bran oil. Finally, retinoids are present in particular in liver, egg yolk and dairy products.
  • the lipophilic bioactive compound is obtained from tomatoes, for example tomato puree or a tomato extract.
  • the presence of lycopene in tomatoes is advantageous for the present invention.
  • the bioactive compound can also be a soybean extract. It is also possible to have a mixture of tomato extract and of soybean extract.
  • These extracts are obtained by conventional methods, with the preferred totmato extract being a lipidic extract obtained by use of a solvent such as ethyl acetate, and the soybean extract being obtained from the ethanol/hot water extraction of soy which has been initially defatted by treatment by hexane.
  • composition according to the invention can be provided in the form of a powder, liquid or gel.
  • the present invention provides a composition comprising a lipophilic bioactive compound which has a better bioavailability than the compound alone.
  • these compositions may be in the form of a highly water-dispersible composition, if the powder form is chosen. In this instance, the powder is dispersible in water at ambient temperature.
  • Another feature of the invention is to protect and preserve the activity of the lipophilic bioactive compound with whey protein.
  • the preferred additive for increasing bioactivity of the compound is whey protein, for example in the form of whey protein isolate.
  • whey protein is understood to mean a product comprising at least 80% of whey proteins.
  • the primary composition according to the invention can additionally comprise vitamin E and vitamin C.
  • Vitamin E tocopherol
  • Vitamin C can be of exogenous or endogenous origin. If desired, vitamin C in any conventional form may be added to the composition.
  • the composition additionally comprises one or more of emulsifiers, stabilizers and other additives.
  • emulsifiers compatible in the food field, such as phospholipids, for example lecithin, polyoxyethylene sorbitan mono- or tristearate, monolaurate, monopalmitate, mono- or trioleate, a mono- or diglyceride.
  • Use may also be made of any type of stabilizer that is known in the food business, in cosmetics or in pharmaceuticals.
  • Use is made, as additives, of flavorings, colorants and any other additive known in the food business, in cosmetics or in pharmaceuticals.
  • the lipophilic bioactive compound is preferably present in an amount of about 0.05 to 50% by weight of the composition and the whey protein is present in an amount of about 5 to 90% of the composition. Also, the whey protein and lipophilic bioactive compound may be present in a weight ratio of at least about 1:1 to 500:1, preferably from about 1.5:1 to 250:1 and more preferably about 2:1 to 20:1.
  • the primary composition comprises tomato oleoresin, soybean extract and whey protein.
  • tomato oleoresin is understood to mean, in the present description, a lipid extract of the tomato plant, including carotenoids, such as lycopene, triglycerides, phospholipids, tocopherol and other less significant compounds.
  • sibean extract is understood to mean a soybean extract comprising a high content of isoflavone. It is also possible to envisage other carotenoid-comprising plants, in particular melons, guavas, grapefruit, apricots, rosehips, carrots, peaches and oranges.
  • the present invention additionally relates to an oral composition
  • an oral composition comprising the primary composition described above in a foodstuff, in a food supplement, in a cosmetic preparation or in a pharmaceutical preparation.
  • This orally ingestible composition makes it possible to enhance the bioavailability of the lipophilic bioactive compound in the body and to slow down the ageing of the skin.
  • Mention may be made, as foodstuff supplemented by the above primary composition, of yogurts, liquid drinks, chocolate, ice creams, cereals, chocolate powders, coffee, culinary products, such as mayonnaise, tomato puree or salad dressings, infant nutrition products, enteral nutrition products or pet foods.
  • the powder is dissolved in the above-mentioned foods or drinks so as to have a daily intake of between about 0.001 and 50 mg of lipophilic bioactive compound, for example such as lycopene.
  • a daily intake of the order of about 5 to 20 mg per day is preferably envisaged.
  • a food supplement in the form of sugar-coated tablets, pills, gelatin capsules, a syrup, a gel, a cream or lozenges with a dose of about 0.001 to 100% of the primary composition, which can then be taken directly with water or by any other known means.
  • This supplement may also include a sweetener, a stabilizer, an additive, a flavoring or a colorant.
  • the oral composition can also be a cosmetic preparation comprising the primary composition and a compound active with respect to the skin known to a person skilled in the art.
  • the oral composition can also be a pharmaceutical preparation comprising the primary composition and a pharmaceutical compound, for example a compound in topical application or which can be orally ingested.
  • the invention also relates to a cosmetic composition
  • a cosmetic composition comprising the primary composition described above.
  • the content of primary composition is between 10 ⁇ 10 and 10%.
  • the cosmetic composition preferably comprises between 10 ⁇ 8 and 5% of lipophilic bioactive compound.
  • composition which can be used topically additionally comprises a fat or an oil which can be used in cosmetics, for example those mentioned in the CTFA work, Cosmetic Ingredients Handbook, Washington. It is also possible to add other cosmetically active ingredients.
  • the composition additionally comprises a structuring agent and an emulsifier.
  • the present invention additionally relates to the use of the oral composition or of the cosmetic composition described above for protecting the tissues of the skin against ageing, in particular for inhibiting damage to the skin and/or mucous membranes by inhibiting collagenases and enhancing the synthesis of collagen.
  • the present invention additionally relates to the process for the preparation of the primary composition described above, in which the whey protein is mixed with the lipophilic bioactive compound.
  • the whey protein is dissolved in water
  • the lipophilic bioactive compound is dissolved in a solvent
  • a dispersion is obtained.
  • the dispersion is heat-treated to produce a gel.
  • the dispersion is dried by spraying or by lyophilization to produce a powder.
  • the composition according to the invention may be directly usable as is or as a mixture, as will be explained below.
  • the whey protein is dissolved in water at a temperature in the region of or slightly greater than ambient temperature.
  • An oleoresin which comprises between 1 and 40% of lycopene is used. The amounts are given as weight/weight.
  • the ratio of the said oleoresin to the solvent is of the order of 1:1 to 1:900 by weight.
  • the solvent is any type of solvent compatible with the food business, cosmetics or pharmaceuticals.
  • the solvent is preferably acetone, ethanol or isopropanol.
  • a solvent/water ratio by volume of the order of 60/40 is chosen.
  • the mixture is left to stand for 30 to 60 min at a temperature slightly higher than ambient temperature, for example of the order of 30° C., and the first operation is to drive off the solvent under a moderate vacuum.
  • moderate vacuum is understood to mean a vacuum of between 200 and 300 mbar. If a powder is desired, the water is removed, either under vacuum or by spraying or by lyophilization. The term “vacuum” is understood to mean a vacuum of between 40 and 50 mbar. If a gel is desired, the emulsion is heated or any other technique known to a person skilled in the art for preparing the said gel is employed.
  • the lipophilic bioactive compound is mixed with a solvent
  • composition obtained is mixed with the whey protein powder, and
  • the solvent is evaporated to produce a powder composition.
  • the lipophilic bioactive compound is mixed directly with the whey powder (optionally comprising a soybean extract) to produce the primary composition according to the invention.
  • This solution is subsequently spray dried.
  • a dispersion of 550 g of oleoresin of Example 1 with an emulsifier in ethanol is prepared. This dispersion is mixed with 1 100 g of whey protein and 1 100 g of soybean extract (comprising 40% of isoflavone). The solvent is driven off to produce a powder.
  • the powder thus obtained is mixed with ascorbic acid and other additives, such as one or more sweeteners, thickeners and food additives, making possible preparation in the form of sugar-coated tablets.
  • the mixture obtained is subsequently sugar-coated.
  • Sugar-coated tablets of the order of 700 mg comprising 33 mg of lycopene, 70 mg of soybean extract, 70 mg of whey protein, 40 mg of ascorbic acid, the remainder being sweeteners, thickeners and food additives, to arrive at 700 mg, are thus prepared.
  • a milk for the face is prepared comprising 7% of liquid petrolatum, 2% of powder according to Example 1, 3% of glyceryl monostearate, polyethylene glycol stearate, 0.4% of carboxyvinyl polymer, 0.7% of stearyl alcohol, 3% of soybean proteins, 0.4% of NaOH and a preservative, and the remainder to 100 being water.
  • a gel for the face is prepared comprising 10% of glycerol, 2% of powder according to Example 1, 1% of disodium cocoamphodiacetate and a preservative, and the remainder to 100 being water.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
US10/057,660 2000-05-30 2002-01-25 Primary composition comprising a lipophilic bioactive compound Abandoned US20020107292A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/004,409 US20050106219A1 (en) 2000-05-30 2004-12-03 Primary composition comprising a lipophilic bioactive compound
US11/553,847 US7588781B2 (en) 2000-05-30 2006-10-27 Method for increasing bioavailability of lipophilic bioactive compounds
US12/353,730 US8455004B2 (en) 2000-05-30 2009-01-14 Primary composition comprising a lipophilic bioactive compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00111542 2000-05-30
EP00111542.7 2000-05-30
PCT/EP2001/006145 WO2001091588A1 (fr) 2000-05-30 2001-05-29 Composition primaire contenant un compose bioactif lipophile

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2001/006145 Continuation-In-Part WO2001091588A1 (fr) 2000-05-30 2001-05-29 Composition primaire contenant un compose bioactif lipophile
PCT/EP2001/006145 Continuation WO2001091588A1 (fr) 2000-05-30 2001-05-29 Composition primaire contenant un compose bioactif lipophile

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/004,409 Continuation-In-Part US20050106219A1 (en) 2000-05-30 2004-12-03 Primary composition comprising a lipophilic bioactive compound
US11/553,847 Division US7588781B2 (en) 2000-05-30 2006-10-27 Method for increasing bioavailability of lipophilic bioactive compounds

Publications (1)

Publication Number Publication Date
US20020107292A1 true US20020107292A1 (en) 2002-08-08

Family

ID=8168868

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/057,660 Abandoned US20020107292A1 (en) 2000-05-30 2002-01-25 Primary composition comprising a lipophilic bioactive compound
US11/553,847 Expired - Fee Related US7588781B2 (en) 2000-05-30 2006-10-27 Method for increasing bioavailability of lipophilic bioactive compounds
US12/353,730 Expired - Fee Related US8455004B2 (en) 2000-05-30 2009-01-14 Primary composition comprising a lipophilic bioactive compound

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/553,847 Expired - Fee Related US7588781B2 (en) 2000-05-30 2006-10-27 Method for increasing bioavailability of lipophilic bioactive compounds
US12/353,730 Expired - Fee Related US8455004B2 (en) 2000-05-30 2009-01-14 Primary composition comprising a lipophilic bioactive compound

Country Status (17)

Country Link
US (3) US20020107292A1 (fr)
EP (1) EP1289383B1 (fr)
JP (2) JP4937483B2 (fr)
KR (1) KR20020019594A (fr)
CN (1) CN100374044C (fr)
AT (1) ATE324800T1 (fr)
AU (1) AU781526B2 (fr)
BR (1) BR0106674A (fr)
CA (1) CA2380451C (fr)
DE (1) DE60119315T2 (fr)
DK (1) DK1289383T3 (fr)
ES (1) ES2262658T3 (fr)
HK (1) HK1050614A1 (fr)
PL (1) PL203142B1 (fr)
PT (1) PT1289383E (fr)
WO (1) WO2001091588A1 (fr)
ZA (1) ZA200201665B (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
US20040071745A1 (en) * 2000-10-26 2004-04-15 Societe L'oreal S.A. Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging
US20050051419A1 (en) * 2003-09-10 2005-03-10 Zima George Chester Process for the recovery of a phytolipid composition
WO2005075575A1 (fr) * 2004-02-10 2005-08-18 Nestec S.A. Compositions contenant des isomeres cis d'un compose carotenoide
US20060246129A1 (en) * 2005-04-29 2006-11-02 Linardakis Nikos M Composition for use in treatment of sleep problems and method for same
US20060286187A1 (en) * 2003-08-21 2006-12-21 Nestec S.A. Natural lycopene concentrate and method for production thereof
WO2007003598A1 (fr) * 2005-07-04 2007-01-11 Basf Aktiengesellschaft Suspensions aqueuses de substances actives difficilement solubles dans l'eau ou insolubles dans l'eau et poudres seches produites a partir desdites suspensions
US20070010460A1 (en) * 2005-06-22 2007-01-11 Btg International Limited Multiple sclerosis therapy and diagnosis
WO2007027092A2 (fr) * 2005-09-02 2007-03-08 Campina Nederland Holding B.V. Produit oral destine a l'hydratation de la peau
EP1809110A2 (fr) * 2004-10-26 2007-07-25 Lycored Natural Products Industries Ltd Procede d'enrichissement d'aliments a l'aide de phytonutriments et produits alimentaires ainsi obtenus
US20080318875A1 (en) * 2003-12-22 2008-12-25 Rakesh Chibber Core 2 Glcnac-T Inhibitors
US7588781B2 (en) 2000-05-30 2009-09-15 Nestec S.A. Method for increasing bioavailability of lipophilic bioactive compounds
US20100048496A1 (en) * 2005-07-06 2010-02-25 Btg International Limited Core 2 GlcNAc-T inhibitors
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US20100256077A1 (en) * 2003-12-22 2010-10-07 Btg International Limited Core 2GlcNAc-T inhibitors
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP2275096A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
WO2011123760A2 (fr) * 2010-04-01 2011-10-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogels d'isolat de protéine de lactosérum et leurs utilisations
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
WO2013079967A1 (fr) 2011-12-02 2013-06-06 Ip Science Limited Produits alimentaires à base de cacao
WO2013088156A1 (fr) 2011-12-14 2013-06-20 Ip Science Limited Produits alimentaires à base de matière grasse
EP1727434B2 (fr) † 2004-03-19 2016-08-31 Nestec S.A. Administration des ingrédients fonctionnels
US9737602B2 (en) 2011-01-31 2017-08-22 Ip Science Limited Carotenoid particles and uses thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161031A (ja) * 2000-11-27 2002-06-04 Noevir Co Ltd 皮膚外用剤
FR2855969B1 (fr) * 2003-06-13 2012-11-30 Coletica Stimulation de l'activite d'une isoforme de lysyl oxydase pour lutter contre certaines pathologies dues a une elastogenese incomplete, absente ou desorganisee
US11039999B2 (en) * 2004-06-25 2021-06-22 Ferrosan Aps Compositions suitable for treating cutaneous signs of aging
JP4700313B2 (ja) * 2004-09-27 2011-06-15 サントリーホールディングス株式会社 プロアントシアニジン及びスフィンゴ脂質を含む組成物
JP2006094739A (ja) * 2004-09-29 2006-04-13 Asama Chemical Co Ltd 乳清タンパク・ココア食品
KR100509681B1 (ko) * 2005-05-27 2005-08-23 주식회사 렉스진바이오텍 포유동물의 초유 또는 유즙 유래의 유청분리분획을포함하는 성장 촉진용 식품 조성물
GB0515035D0 (en) * 2005-07-21 2005-08-31 Cambridge Theranostics Ltd Treatment of atherosclerotic conditions
GB0605949D0 (en) * 2006-03-24 2006-05-03 Quest Int Serv Bv Milk product for skin treatment
JP2009535303A (ja) * 2006-04-13 2009-10-01 ケムメディカ・リミテッド 代謝機能障害の治療のためのリコピン
IL176668A0 (en) * 2006-07-02 2006-10-31 Ibr Ltd Colorless carotenoids for skin whitening
PT2051595E (pt) * 2006-08-08 2016-02-09 Nestec Sa Composições biodisponíveis e estáveis de isómeros de carotenoides para a pele e cabelo
FR2913337A1 (fr) * 2007-03-08 2008-09-12 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganismes
FR2939040B1 (fr) 2008-12-03 2013-08-09 Laboratoires Inneov Snc Association de lycopene, polyphenol et vitamines pour le soin des matieres keratiniques
US20110223256A1 (en) * 2010-03-11 2011-09-15 Stokely-Van Camp, Inc. Method For Stabilizing Flavonoid Aqueous Dispersion
FR2974296B1 (fr) 2011-04-19 2013-05-24 Inneov Lab Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c en tant qu'actif pour l'hydratation de la peau
FR2974300B1 (fr) 2011-04-19 2013-05-10 Inneov Lab Utilisation d'une combinaison d'un carotenoide, d'un phytoestrogene et de la vitamine c pour la prevention et/ou le traitement de desordres pigmentaires
FR2996136B1 (fr) 2012-09-28 2015-01-02 Inneov Lab Utilisation d'une association d'au moins un acide gras polyinsature et d'au moins un carotenoide pour ameliorer la qualite des ongles.
FR2996135A1 (fr) 2012-09-28 2014-04-04 Inneov Lab Composition orale pour renforcer la tolerance cutanee suite a une administration topique d'un compose retinoide.
FR3014688B1 (fr) 2013-12-12 2016-12-16 Laboratoires Inneov S N C Composition a base d'acide gras polyinsature et de carotenoide destinee a une administration par voie orale pour ameliorer la qualite de la chevelure
CN108042462B (zh) * 2017-11-28 2019-10-29 江西登云健康美业互联有限公司 一种稳定性能好、极易吸收的高滋润生物霜及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522743A (en) * 1981-05-15 1985-06-11 Basf Aktiengesellschaft Preparation of finely divided pulverulent carotinoid and retinoid compositions
US4530788A (en) * 1982-12-03 1985-07-23 Stauffer Chemical Company Oil seed proteins evidencing improved functionality
US5235315A (en) * 1992-01-02 1993-08-10 Armatron International, Inc. Self test for obstacle detection system
US5601760A (en) * 1994-09-01 1997-02-11 The Regents Of The University Of California, A California Corporation Milk derived whey protein-based microencapsulating agents and a method of use
US5643623A (en) * 1995-06-07 1997-07-01 Mars Incorporated Health food product and its uses
US5706526A (en) * 1996-10-15 1998-01-13 Huang; Ann Swimming goggles
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US6203805B1 (en) * 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521691A (en) * 1974-07-31 1978-08-16 Bush Boake Allen Ltd Oleoresin emulsions
CH613609A5 (en) * 1975-10-02 1979-10-15 Hoffmann La Roche Method for preparing stable and protected food additives
CH662707A5 (fr) * 1985-03-19 1987-10-30 Nestle Sa Preparation de produits alimentaires gelifies.
JPH0791195B2 (ja) * 1986-12-27 1995-10-04 旭化成工業株式会社 活性型ビタミンｄ類の経口投与用カプセル剤
DE3702030A1 (de) * 1987-01-24 1988-08-04 Basf Ag Pulverfoermige, wasserdispergierbare carotinoid-zubereitungen und verfahren zu ihrer herstellung
JP2654445B2 (ja) * 1987-03-04 1997-09-17 株式会社富士薬品 天然アルブミンを担体とした医薬組成物及びその製法
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
AU614537B2 (en) * 1987-09-09 1991-09-05 Richard B. Bankert Use of milk fat globules as carriers for drugs and as microflotation devices in immunoassays and cell molecular fractionation
AU611366B2 (en) * 1988-02-12 1991-06-06 Kao Corporation Milk replacer for infant cattle and method for breeding infant cattle using the same
AU619856B2 (en) * 1988-06-16 1992-02-06 Unilever Plc Edible plastic composition
JPH0748992B2 (ja) * 1990-04-16 1995-05-31 日本油脂株式会社 血栓防止用粉末組成物
JP3027858B2 (ja) * 1991-01-30 2000-04-04 日本油脂株式会社 高度不飽和脂肪酸含有組成物の製造方法
JPH07101881A (ja) * 1993-09-30 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JP2750281B2 (ja) 1995-06-15 1998-05-13 睦憲 藤原 高コレステロール血症治療剤
JP3188657B2 (ja) * 1997-07-24 2001-07-16 株式会社第一化成 錠剤又は顆粒状製品
JPH11169134A (ja) * 1997-12-17 1999-06-29 Nippon Del Monte Corp タンパク質含有飲食品の着色方法
DE19841930A1 (de) 1998-09-14 2000-03-16 Basf Ag Stabile, pulverförmige Lycopin-Formulierungen, enthaltend Lycopin mit einem Kristallinitätsgrad von größer 20%
US6042815A (en) * 1998-10-21 2000-03-28 Revlon Consumer Products Corporation Water and oil emulsion solid cosmetic composition
DK1289383T3 (da) 2000-05-30 2006-08-14 Nestle Sa Grundsammensætning indeholdende en lipofil bioaktiv forbindelse

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522743A (en) * 1981-05-15 1985-06-11 Basf Aktiengesellschaft Preparation of finely divided pulverulent carotinoid and retinoid compositions
US4530788A (en) * 1982-12-03 1985-07-23 Stauffer Chemical Company Oil seed proteins evidencing improved functionality
US5235315A (en) * 1992-01-02 1993-08-10 Armatron International, Inc. Self test for obstacle detection system
US5601760A (en) * 1994-09-01 1997-02-11 The Regents Of The University Of California, A California Corporation Milk derived whey protein-based microencapsulating agents and a method of use
US5643623A (en) * 1995-06-07 1997-07-01 Mars Incorporated Health food product and its uses
US5706526A (en) * 1996-10-15 1998-01-13 Huang; Ann Swimming goggles
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US6203805B1 (en) * 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588781B2 (en) 2000-05-30 2009-09-15 Nestec S.A. Method for increasing bioavailability of lipophilic bioactive compounds
US20040071745A1 (en) * 2000-10-26 2004-04-15 Societe L'oreal S.A. Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging
US20090105330A1 (en) * 2000-10-26 2009-04-23 L'oreal Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
US8795743B2 (en) 2003-08-21 2014-08-05 Nestec S.A. Natural lycopene concentrate and method for production thereof
AU2004267942B2 (en) * 2003-08-21 2009-10-08 Nestec S.A. Natural lycopene concentrate and method for production therof
US8507014B2 (en) 2003-08-21 2013-08-13 Nestec S.A. Natural lycopene concentrate and method for production thereof
US20060286187A1 (en) * 2003-08-21 2006-12-21 Nestec S.A. Natural lycopene concentrate and method for production thereof
US7491412B2 (en) 2003-09-10 2009-02-17 Eastman Chemical Company Process for the recovery of a phytolipid composition
US20050053712A1 (en) * 2003-09-10 2005-03-10 Zima George Chester Process for the recovery of a phytolipid composition
US20080138450A1 (en) * 2003-09-10 2008-06-12 Eastman Chemical Company Process for the recovery of a phytolipid composition
US7416756B2 (en) 2003-09-10 2008-08-26 Eastman Chemical Company Process for the recovery of a phytolipid composition
US20050051419A1 (en) * 2003-09-10 2005-03-10 Zima George Chester Process for the recovery of a phytolipid composition
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US7906493B2 (en) 2003-12-22 2011-03-15 Btg International Limited Core 2 GlcNAc-T inhibitors
US20100256077A1 (en) * 2003-12-22 2010-10-07 Btg International Limited Core 2GlcNAc-T inhibitors
US20080318875A1 (en) * 2003-12-22 2008-12-25 Rakesh Chibber Core 2 Glcnac-T Inhibitors
US20070098820A1 (en) * 2004-02-10 2007-05-03 Nestec S.A. Compositions containing cis-isomers of a carotenoid compound and process
WO2005075575A1 (fr) * 2004-02-10 2005-08-18 Nestec S.A. Compositions contenant des isomeres cis d'un compose carotenoide
EP1727434B2 (fr) † 2004-03-19 2016-08-31 Nestec S.A. Administration des ingrédients fonctionnels
EP1809110A2 (fr) * 2004-10-26 2007-07-25 Lycored Natural Products Industries Ltd Procede d'enrichissement d'aliments a l'aide de phytonutriments et produits alimentaires ainsi obtenus
EP1809110A4 (fr) * 2004-10-26 2009-08-19 Lycored Natural Prod Ind Ltd Procede d'enrichissement d'aliments a l'aide de phytonutriments et produits alimentaires ainsi obtenus
US20060246129A1 (en) * 2005-04-29 2006-11-02 Linardakis Nikos M Composition for use in treatment of sleep problems and method for same
US20070010460A1 (en) * 2005-06-22 2007-01-11 Btg International Limited Multiple sclerosis therapy and diagnosis
WO2007003598A1 (fr) * 2005-07-04 2007-01-11 Basf Aktiengesellschaft Suspensions aqueuses de substances actives difficilement solubles dans l'eau ou insolubles dans l'eau et poudres seches produites a partir desdites suspensions
US20080220071A1 (en) * 2005-07-04 2008-09-11 Basf Aktiengesellschaft Aqueous Suspensions of Poorly Water-Soluble and Water-Insoluble Active Ingredients and Drying Powder Produced Therefrom
US20100048496A1 (en) * 2005-07-06 2010-02-25 Btg International Limited Core 2 GlcNAc-T inhibitors
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP2275095A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258358A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275096A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258359A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
WO2007027092A2 (fr) * 2005-09-02 2007-03-08 Campina Nederland Holding B.V. Produit oral destine a l'hydratation de la peau
US20080199512A1 (en) * 2005-09-02 2008-08-21 Steffi Dudek Oral Composition For Moisturizing Skin
WO2007027092A3 (fr) * 2005-09-02 2007-05-10 Campina Nederland Holding Bv Produit oral destine a l'hydratation de la peau
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
EP2382975A2 (fr) 2006-05-09 2011-11-02 Braincells, Inc. Neurogénèse par modulation d'angiotensine
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
WO2011123760A3 (fr) * 2010-04-01 2012-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogels d'isolat de protéine de lactosérum et leurs utilisations
WO2011123760A2 (fr) * 2010-04-01 2011-10-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogels d'isolat de protéine de lactosérum et leurs utilisations
US9758558B2 (en) 2010-04-01 2017-09-12 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Whey protein isolate hydrogels and their uses
US9737602B2 (en) 2011-01-31 2017-08-22 Ip Science Limited Carotenoid particles and uses thereof
WO2013079967A1 (fr) 2011-12-02 2013-06-06 Ip Science Limited Produits alimentaires à base de cacao
WO2013088156A1 (fr) 2011-12-14 2013-06-20 Ip Science Limited Produits alimentaires à base de matière grasse

Also Published As

Publication number Publication date
KR20020019594A (ko) 2002-03-12
EP1289383A1 (fr) 2003-03-12
ES2262658T3 (es) 2006-12-01
US20070071830A1 (en) 2007-03-29
BR0106674A (pt) 2002-04-30
WO2001091588A1 (fr) 2001-12-06
AU781526B2 (en) 2005-05-26
US20090123542A1 (en) 2009-05-14
JP5021708B2 (ja) 2012-09-12
HK1050614A1 (en) 2003-07-04
AU6749601A (en) 2001-12-11
JP2003534357A (ja) 2003-11-18
US8455004B2 (en) 2013-06-04
EP1289383B1 (fr) 2006-05-03
US7588781B2 (en) 2009-09-15
CA2380451C (fr) 2010-03-30
PL352037A1 (en) 2003-07-28
DE60119315D1 (de) 2006-06-08
JP2010059163A (ja) 2010-03-18
PT1289383E (pt) 2006-08-31
ATE324800T1 (de) 2006-06-15
JP4937483B2 (ja) 2012-05-23
CA2380451A1 (fr) 2001-12-06
CN100374044C (zh) 2008-03-12
DE60119315T2 (de) 2006-08-31
DK1289383T3 (da) 2006-08-14
ZA200201665B (en) 2003-05-27
PL203142B1 (pl) 2009-08-31
CN1380813A (zh) 2002-11-20

Similar Documents

Publication Publication Date Title
US7588781B2 (en) Method for increasing bioavailability of lipophilic bioactive compounds
EP1716210B1 (fr) Compositions contenant des isomères cis de caroténoides et procédé
US8568806B2 (en) Stable and bioavailable compositions of isomers of lycopene for skin and hair
JP2003534357A5 (fr)
US20150258038A1 (en) Stable and bioavailable compositions of isomers of carotenoids for skin and hair
US20050106219A1 (en) Primary composition comprising a lipophilic bioactive compound
JP2017145235A (ja) コラゲナーゼ阻害剤
US8216619B2 (en) Stable and bioavailable compositions of isomers of carotenoids for skin and hair

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BORTLIK, KARLHEINZ;SAUCY, FRANCOISE;DURUZ, ELAINE;AND OTHERS;REEL/FRAME:012823/0530;SIGNING DATES FROM 20020307 TO 20020322

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION